1095003-82-9

Upstream product

• 123-75-1 pyrrolidine 
• 1095005-58-5 methyl 3-[(cyanomethyl)amino]-4-methylbenzoate 
• 1095005-75-6 (S)-2-methyl-N-[(1R)-1-[2-(2-hydroxyethoxy)phenyl]propyl]-2-propanesulfinamide 
• 1095005-59-6 methyl 3-(3,5-dibromo-2-oxopyrazin-1(2H)-yl)-4-methylbenzoate 
• 22042-72-4 2-(2-hydroxyethoxy)benzaldehyde 
• 18595-18-1 3-amino-4-methyl benzoic acid methyl ester 
• 1095005-78-9 (R)-N-cyclopropyl-3-(3-(1-(2-(2-hydroxyethoxy)phenyl)propylamino)-2-oxopyrazin-1(2H)-yl)-4-methylbenzamide 

Relevant academic research and scientific papers

The discovery and evaluation of 3-amino-2(1H)-pyrazinones as a novel series of selective p38α MAP kinase inhibitors

The discovery and optimisation of a novel series of potent and selective p38α inhibitors is described. Evaluating the structure-activity relationship of an aminoalkyl substituent at the 3 position of the 2(1H)-pyrazinone core, p38α potency was increased 20000-fold. The most advanced compound (25) demonstrated excellent in vivo properties suitable for an inhaled route of administration.

PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES

The present invention relates to py razinone derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6 and R7 are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.